[go: up one dir, main page]

NO982036D0 - A compound suitable for the treatment of traumatic brain injury - Google Patents

A compound suitable for the treatment of traumatic brain injury

Info

Publication number
NO982036D0
NO982036D0 NO982036A NO982036A NO982036D0 NO 982036 D0 NO982036 D0 NO 982036D0 NO 982036 A NO982036 A NO 982036A NO 982036 A NO982036 A NO 982036A NO 982036 D0 NO982036 D0 NO 982036D0
Authority
NO
Norway
Prior art keywords
treatment
brain injury
traumatic brain
compound suitable
compound
Prior art date
Application number
NO982036A
Other languages
Norwegian (no)
Other versions
NO982036L (en
Inventor
Brian R Pike
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO982036D0 publication Critical patent/NO982036D0/en
Publication of NO982036L publication Critical patent/NO982036L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO982036A 1995-11-06 1998-05-05 A compound suitable for the treatment of traumatic brain injury NO982036L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
NO982036D0 true NO982036D0 (en) 1998-05-05
NO982036L NO982036L (en) 1998-06-25

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982036A NO982036L (en) 1995-11-06 1998-05-05 A compound suitable for the treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (en)
JP (1) JPH11514654A (en)
KR (1) KR19990067353A (en)
AU (1) AU706594B2 (en)
BG (1) BG63150B1 (en)
BR (1) BR9611396A (en)
CA (1) CA2234824A1 (en)
CZ (1) CZ287441B6 (en)
EA (1) EA000531B1 (en)
HU (1) HUP9901051A2 (en)
IS (1) IS4726A (en)
NO (1) NO982036L (en)
NZ (1) NZ321546A (en)
PL (1) PL326490A1 (en)
SK (1) SK58198A3 (en)
TR (1) TR199800801T2 (en)
WO (1) WO1997017074A1 (en)
ZA (1) ZA969320B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (en) * 1997-07-01 2000-12-13 Lundbeck & Co As H SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME.
RU2266737C1 (en) * 2004-04-12 2005-12-27 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Россиской Академии Наук Method and preparation for treating the cases of hemorrhagic stroke
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
BG102480A (en) 1999-01-29
CA2234824A1 (en) 1997-05-15
AU7490096A (en) 1997-05-29
WO1997017074A1 (en) 1997-05-15
SK58198A3 (en) 1998-10-07
CZ287441B6 (en) 2000-11-15
EA000531B1 (en) 1999-10-28
CZ138998A3 (en) 1998-10-14
EA199800434A1 (en) 1998-10-29
KR19990067353A (en) 1999-08-16
ZA969320B (en) 1997-05-30
PL326490A1 (en) 1998-09-28
MX9803432A (en) 1998-09-30
BG63150B1 (en) 2001-05-31
HUP9901051A2 (en) 2000-03-28
EP0866706A1 (en) 1998-09-30
NO982036L (en) 1998-06-25
IS4726A (en) 1998-04-27
BR9611396A (en) 1999-07-13
NZ321546A (en) 2000-12-22
TR199800801T2 (en) 1998-08-21
AU706594B2 (en) 1999-06-17
JPH11514654A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
NO965377L (en) Indolinone compounds for the treatment of diseases
NO976063D0 (en) Procedure for the treatment of diabetes
NO961483D0 (en) Process for the treatment of oily formation
NO924461D0 (en) DIPYRIDAMOL FOR THE TREATMENT OF PROLIFERACTIVE DISEASES
NO934547D0 (en) Oral treatment of Helicobacter-in-infection
FI964874A0 (en) Treatment of vegetables
NO963785D0 (en) Process for the treatment of 5HT2B receptor-related conditions
NO991955D0 (en) Process for the treatment of hydrocarbons
NO990225D0 (en) Medications for the treatment of hyperphosphatemia
NO975661D0 (en) Use of bis-1,2,4-triazoles for the preparation of a drug for the treatment of cancer
FI962370A0 (en) Apparatus for the manufacture of tissue
NO953254D0 (en) Substituted azolone derivatives for the treatment of helicobacter diseases
NO178150C (en) One-step process for the preparation of dirithromycin
PT777457E (en) THE USE OF GLYCERYL TRIACETATE FOR THE TREATMENT OF ONICOMICOSES
NO972402D0 (en) Process for the preparation of carriers
NO975660D0 (en) Use of benzimidazoles for the manufacture of a drug for the treatment of liver chemistry
NO982036D0 (en) A compound suitable for the treatment of traumatic brain injury
NO930574D0 (en) PROCEDURE FOR PRODUCING DESFLURAN
EE03384B1 (en) Use of melatonin for the manufacture of a medicament
NO301716B1 (en) Process for the preparation of calcium L-ascorbate-2-phosphate
NO963187D0 (en) Process for the synthesis of gamma-pyrones
NO982582D0 (en) Procedure for treating pain
EE9700235A (en) Benzenamides for the treatment of neurodegenerative diseases
NO973366D0 (en) Procedure for the treatment of multiple sclerosis
NO955082D0 (en) Process for the preparation of glutardialdehyde

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application